people on the move
Sarepta
Sarepta Therapeutics, a company making RNA-based biopharmaceuticals, has appointed its Chief Medical Officer as interim CEO.
Edward Kaye will take over company management effective immediately, replacing Christopher Garabedian, who resigned as President and CEO, also with immediate effect.
Kaye has been Sarepta’s CMO since 2011. He was previously Group VPof Clinical Development at Genzyme, where he supervised clinical development programs for rare diseases, including lysosomal storage diseases and genetic neurological disorders.
Sarepta’s lead drug candidate is eteplirsen for Duchenne Muscular Dystrophy (DMD). The company said it remains on track with plans for a New Drug Application to the FDA in mid-2015.
